Drug From Stony Brook-Developed Anti-Cancer Compounds Now in Clinical Trials
· newswise.com · popularity 16/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at newswise.com →
Summary
A promising new cancer chemotherapeutic agent from a taxane class of natural compounds - anti-cancer agents designed to block cell division and trigger the programmed cell death to treat sold tumors - originally developed by researchers at Stony Brook University has entered human clinical trials.
Found in: Newswise. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 18.